A newly approved migraine drug from Biohaven Pharmaceuticals brought in nearly $10 million for the company during the first full quarter since its launch.
CEO Vlad Coric, MD, says that the launch of Nurtec has exceeded the company’s initial expectations, especially since it coincided with the start of the COVID-19 pandemic in March.